The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%.” - The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, January ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

The most important therapy in Sarepta Therapeutics' portfolio is Elevidys, which last year earned full FDA approval for use in ambulatory Duchenne muscular dystrophy patients. The medicine also ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys (delandistrogene moxeparvovec) as a gene therapy for treating Duchenne ...